Valeant Puts Up $8.7B For PE-Backed Bausch & Lomb
Private equity-backed eye care company Bausch & Lomb Holdings Inc. on Monday signed off on an $8.7 billion deal to fold itself into Valeant Pharmaceuticals International Inc., opting for the sale...To view the full article, register now.
Already a subscriber? Click here to view full article